Taiko Pharmaceutical (4574) Fundamentals 2026 — P/E 25.5x, Revenue Analysis | SniperIQ
Taiko Pharmaceutical (4574) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥13.7B, trading at ¥272.00 on the JPX. This SniperIQ fundamentals page covers Taiko Pharmaceutical's valuation (P/E 25.5x, P/B 1.7x), profitability (net margin 8.7%), revenue (¥6.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Taiko Pharmaceutical's market cap?
Taiko Pharmaceutical (4574) has a market capitalization of approximately ¥13.7B, trading at ¥272.00 on the JPX. Market cap moves with the live share price.
What is Taiko Pharmaceutical's P/E ratio?
Taiko Pharmaceutical's trailing twelve-month P/E ratio is 25.5x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Taiko Pharmaceutical?
Taiko Pharmaceutical runs a net profit margin of 8.7%, a gross margin of 53.6%, and an operating margin of 5.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Taiko Pharmaceutical generate?
Taiko Pharmaceutical reported revenue of ¥6.4B for fiscal year 2025, with net income of ¥923M and earnings per share (EPS) of 18.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Taiko Pharmaceutical pay a dividend?
Taiko Pharmaceutical offers a trailing dividend yield of about 1.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Taiko Pharmaceutical financially healthy?
Taiko Pharmaceutical carries a debt-to-equity ratio of 0.06x and a current ratio of 4.14x, with a market beta of 0.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Taiko Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Taiko Pharmaceutical (4574) the key facts are: market cap ¥13.7B, P/E 25.5x, revenue ¥6.4B, 52-week range 246-335. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Taiko Pharmaceutical's full fundamentals live
Get Taiko Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.